natgillin/translations-raw huggingface dataset:
This vaccine is for oral administration only.
To cepivo je namenjeno izključno za peroralno aplikacijo.
This vaccine is given orally - straight from the tube.
To cepivo se daje peroralno – neposredno iz tube.
This vaccine is indicated for active immunisation against hepatitis B virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis B virus.
Cepivo HBVAXPRO je indicirano za aktivno imunizacijo proti okužbi z vsemi znanimi podtipi virusa hepatitisa B pri posameznikih, starih 16 let ali več, pri katerih obstaja tveganje za izpostavljenost virusu hepatitisa B.
This vaccine is indicated for active immunisation against hepatitis B virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis B virus.
Cepivo HBVAXPRO je indicirano za aktivno imunizacijo proti okužbi z vsemi znanimi podtipi virusa hepatitisa B pri posameznikih od rojstva do 15. leta starosti, pri katerih obstaja tveganje za izpostavljenost virusu hepatitisa B.
This vaccine may contain traces of formaldehyde and potassium thiocyanate which are used during the manufacturing process.
To cepivo lahko v sledeh vsebuje formaldehid in kalijev tiocianat, ki se uporabljata med postopkom izdelave.
This vaccine may contain traces of formaldehyde and potassium thiocyanate, which are used during the manufacturing process.
To cepivo lahko v sledeh vsebuje formaldehid in kalijev tiocianat, ki se uporabljata med postopkom izdelave.
This vaccine may contain traces of formaldehyde and potassium thiocyanate, which are used during the manufacturing process.
To cepivo lahko vsebuje sledove formaldehida in kalijevega tiocianata, ki se uporabljata med postopkom izdelave.
This vaccine should not be given to infants or children with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection unless the potential benefit clearly outweighs the risk of administration.
Cepiva ne dajemo dojenčkom ali otrokom s trombocitopenijo ali kako drugo motnjo strjevanja krvi, pri kateri je intramuskularna aplikacija kontraindicirana, razen v primerih, ko je korist cepljenja očitno večja od potencialnega tveganja.
This vaccine should not be given to infants or children with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection unless the potential benefit clearly outweighs the risk of administration.
S tem cepivom se ne sme cepiti dojenčkov ali otrok s trombocitopenijo ali kako drugo motnjo strjevanja krvi, pri kateri je intramuskularno dajanje kontraindicirano, razen v primerih, ko je korist cepljenja očitno večja od potencialnega tveganja.
This vaccine should only be used after it has been established that the QX-like IBV variant strain is epidemiologically relevant.
To cepivo smemo uporabiti le, ko je ugotovljeno, da je variantni sev podoben QX virusu kužnega bronhitisa epidemiološko pomemben.
This vaccine should under no circumstances be administered into a vein (intravascularly).
To cepivo se pod nobenim pogojem ne sme dajati v žilo (intravaskularno).
This vaccine will be used in situations where it is considered necessary to protect against smallpox in accordance with official recommendations.
To cepivo se bo uporabljalo v primerih, kjer se ocenjuje, da je potrebna zaščita pred črnimi kozami v skladu z uradnimi priporočili.
This value is consistent with data from pivotal clinical studies, where mean changes from baseline in QTcF (Fridericia’s correction) after doses of 500 and 750 mg twice daily were 1.9 and 4.9 msec, respectively.
Ta vrednost sovpada s podatki osrednjih kliničnih študij, pri katerih je bila srednja vrednost sprememb od izhodiščne vrednosti intervala QTcF (Fridericijev popravek) po odmerku 500 mg dvakrat na dan 1,9 ms, po odmerku 750 mg dvakrat na dan pa 4,9 ms.
This veterinary medicinal product can be used during lactation.
Zdravilo za uporabo v veterinarski medicini se lahko se uporablja v obdobju laktacije.
This veterinary medicinal product does not require any special storage conditions.
To zdravilo za uporabo v veterinarski medicini ne zahteva nobenih posebnih pogojev za shranjevanje.
This veterinary medicinal product does not require any special storage conditions.
Za shranjevanje tega zdravila za uporabo v veterinarski medicini ni posebnih navodil.
This veterinary medicinal product does not require any special storage conditions.
Za shranjevanje zdravila ni posebnih omejitev.
This veterinary medicinal product does not require any special storage conditions.
Za shranjevanje zdravila ni posebnih temperaturnih omejitev.
This veterinary medicinal product does not require any special storage conditions.
Za shranjevanjeni posebnih navodil.
This veterinary medicinal product does not require any special temperature storage conditions.
To zdravilo za uporabo v veterinarski medicini ne zahteva nobenih posebnih pogojev za shranjevanje.
This veterinary medicinal product does not require any special temperature storage conditions.
To zdravilo za uporabo v veterinarski medicini ne zahteva nobenih posebnih temperaturnih pogojev za shranjevanje.
This veterinary medicinal product does not require any special temperature storage conditions.
Za shranjevanje zdravila za uporabo v veterinarski medicini ni posebnih temperaturnih omejitev.
This veterinary medicinal product does not require any special temperature storage conditions.
Za shranjevanje zdravila za uporabo v veterinarski medicini ni posebnih temperaturnih pogojev.
This veterinary medicinal product is a systemic insecticide and acaricide that provides: immediate and persistent flea (Ctenocephalides felis and C. canis) killing activity for 12 weeks, immediate and persistent tick (Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus) killing activity for 12 weeks.
To zdravilo za uporabo v veterinarski medicini je sistemski insekticid in akaricid, ki zagotavlja takojšnje in trajno ubijanje bolh (Ctenocephalides felis in C. cnmis ) skozi 12 tednov, takojšnje in trajno ubijanje klopov (Ixodes ricinus in Dermacentor reticulatus skozi 12 tednov.
This veterinary medicinal product is a systemic insecticide and acaricide that provides: immediate and persistent flea (Ctenocephalides felis and Ctenocephalides canis) killing activity for 12 weeks, and immediate and persistent tick (Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus) killing activity for 12 weeks.
To zdravilo za uporabo v veterinarski medicini je sistemski insekticid in akaricid, ki zagotavlja takojšnje in trajno ubijanje bolh (Ctenocephalides felis in Ctenocephalides canis) skozi 12 Tednov in takojšnje in trajno ubijanje klopov skozi 12 tednov (Ixodes ricinus, Rhipicephalus sanguineus in Dermacentor reticulatus).
This veterinary medicinal product is for spot-on application only.
Zdravilo nanašajte samo na kožo.
This veterinary medicinal product is irritating to the eyes and skin.
To zdravilo za uporabo v veterinarski medicini lahko draži oči in kožo.
This veterinary medicinal product is to be applied to the skin surface only.
Zdravilo nanašamo le na površino kože.
This veterinary medicinal product may cause skin sensitisation, allergic reactions and mild eye irritation in humans.
To zdravilo za uporabo v veterinarski medicini lahko povzroči povečano občutljivost kože, alergijske reakcije in blago draženje oči pri ljudeh.
This veterinary medicinal product should be used by an appropriately qualified veterinarian.
To zdravilo za uporabo v veterinarski medicini sme uporabljati samo ustrezno usposobljen doktor veterinarske medicine.
This veterinary medicinal product was well tolerated in collies with a deficient multidrug-resistance- protein 1 (MDR1 -/-) following single oral administration at 3 times the maximum recommended dose.
Zdravilo za uporabo v veterinarski medicini so dobro prenašali koliji z nezadostnim MDR 1 -/- po enkratnem oralnem dajanju 3krat večjega odmerka od priporočenega.
This veterinary medicine does not require any special storage conditions.
Za shranjevanje ni posebnih navodil.
This veterinary medicine has been developed especially for dogs and is not intended for use in humans.
To zdravilo za uporabo veterinarski medicini je bilo razvito posebej za pse in ni namenjeno za uporabo pri ljudeh.
This veterinary medicine is irritating to the eyes and skin.
To zdravilo za uporabo v veterinarski medicini lahko draži oči in kožo.
This veterinary medicine kills fleas (Ctenocephalides felis) on infested cats and prevents further infestations for one month.
Zdravilo za uporabo v veterinarski medicini ubija bolhe (Ctenocephalidec felis) na okuženih mačkah in preprečuje nadaljno okužbo še en mesec po nanosu.
This veterinary medicine should not enter water courses as it is dangerous for fish and other aquatic organisms.
Zdravilo za uporabo v veterinarski medicini ne sme priti v vodotoke, ker je lahko nevarno za ribe in druge vodne organizme.
This vial contains an overfill.
Viala vsebuje prepolnitev.
This volume depends on the quantity of medicine combined with Cuprymina required for administration by the nuclear medicine doctor.
Prostornina je odvisna od količine zdravila, kombiniranega z radiofarmacevtskim predhodnikom Cuprymina, ki jo za injiciranje potrebuje zdravnik nuklearne medicine.
This volume of distribution (approximately 10-15 l for a body weight of 70 kg) is consistent with a medicinal product which distributes into the extracellular fluid.
Ta volumen porazdelitve (približno 10–15 l pri telesni masi 70 kg) je skladen z zdravili, ki se porazdelijo v zunajcelično tekočino.
This vomiting is most likely caused by a local effect on the small intestines.
Bruhanje najverjetneje povzroči lokalni učinek na tanko črevo.
This waiver does however not extend to any diagnostic or therapeutic uses of the product when linked to a carrier molecule.
Ta pregled se ne nanaša na nobeno od diagnostičnih ali terapevtskih uporab radiofarmacevtskega predhodnika, kadar je vezan na nosilno molekulo.
This warning is not only restricted to medicinal products but also to a considerable number of foods and nutritional products aimed at children, such as cola drinks, which contain significant quantities of caffeine or chocolate, which contains trace amounts of theophylline.
To opozorilo se ne nanaša le na zdravila, ampak tudi na veliko živil in prehranskih izdelkov za otroke, npr. kola pijače, ki vsebujejo znatne količine kofeina ali čokolada, ki vsebuje sledove teofilina.
This was a composite endpoint which had the following skeletal related events (SREs) as sub-components:
Cilj raziskave je sestavljalo več, z okostjem povezanih dogodkov (SRE – skeletal related event):
This was a composite endpoint which had the following skeletal related events (SREs) as sub-components:
Cilj raziskave je sestavljalo več, z okostjem povezanih, dogodkov (SRE – skeletal related event):
This was a controlled, randomized study comparing Oncaspar to another pegylated asparaginase product in combination with multi-agent chemotherapy in the first line treatment.
To je bila kontrolirana, randomizirana študija, ki je primerjala zdravilo Oncaspar z drugo pegilirano asparaginazo v kombinaciji s polikemoterapijo prve izbire.
This was a double-blind, placebo-controlled, randomised study in pre-term or term neonates (gestational age 36–42 weeks) with PPHN.
To je bila dvojno-slepa, s placebom nadzorovana, randomizirana študija pri nedonošenih in donošenih novorojenčkih (gestacijska starost 36 - 42 tednov) s PPHN.
This was a phase III randomised, active-controlled, open-label trial investigating Avastin 10 mg/kg in combination with leucovorin with 5-fluorouracil bolus and then 5-fluorouracil infusional, with IV oxaliplatin (FOLFOX-4), administered on a 2-weekly schedule in previously-treated patients (second line) with advanced colorectal cancer.
To je bilo randomizirano, aktivno kontrolirano, odprto preskušanje faze III, ki je proučevalo zdravilo Avastin v odmerku 10 mg/kg v kombinaciji z levkovorinom in bolusom 5-fluorouracila, sledila je infuzija 5-fluorouracila z oksaliplatinom intravensko (shema FOLFOX-4) pri bolnikih z napredovalim rakom debelega črevesa in danke, ki so bili predhodno zdravljeni (druga linija).
This was a Phase III randomised, controlled, open-label trial investigating Avastin 5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with fluoropyrimidine-based chemotherapy versus fluoropyrimidine-based chemotherapy alone in patients with mCRC who have progressed on a first- line bevacizumab-containing regimen.
To je bilo randomizirano, kontrolirano, odprto preskušanje faze III, s katerim so pri bolnikih z metastatskim rakom debelega črevesa in danke, pri katerih je po prvi liniji zdravljenja z bevacizumabom prišlo do napredovanja bolezni, proučevali zdravilo Avastin v odmerku 5,0 mg/kg telesne mase vsaka 2 tedna ali v odmerku 7,5 mg/kg telesne mase vsake 3 tedne v kombinaciji s kemoterapijo, osnovano na fluoropirimidinu, v primerjavi s samostojno kemoterapijo na osnovi fluoropirimidina.
This was a population of heavily pretreated patients, as 46% had received prior BMT and 73% a prior multi-agent chemotherapy.
To je bila skupina že prej močno zdravljenih bolnikov, saj jih je pred začetkom preizkušanja 46 % imelo presaditev kostnega mozga (BMT – bone marrow transplantation), 73 % pa kemoterapijo z več zdravili.
This was a randomised, double-blind, phase II clinical trial investigating Avastin 10 mg/kg in a 2 weekly schedule with the same dose of Avastin in combination with 150 mg daily erlotinib, in patients with metastatic clear cell RCC.
To je bilo randomizirano, dvojno slepo klinično preskušanje faze II, ki je pri bolnikih z metastatskim svetloceličnim karcinomom ledvičnih celic proučevalo zdravilo Avastin, dajano v odmerku 10 mg/kg v dvotedenski shemi, in enak odmerek zdravila Avastin v kombinaciji s 150 mg erlotiniba na dan.
This was achieved with a stable insulin dose (40.1 UI).
Ta izid je bil dosežen ob stabilnem odmerku insulina (40,1 i.e.).
This was associated with a reported improvement in symptoms affecting the cardiovascular system (heart and blood vessels) and the development of the nervous system in around three quarters of the patients taking Cystadane.
To je bilo povezano z izboljšanjem simptomov v zvezi s kardiovaskularnim sistemom (srce in ožilje) ter razvojem živčnega sistema pri približno treh četrtinah bolnikov, ki so prejemali zdravilo Cystadane.
This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.
To je mogoče pripisati vplivu pioglitazona na zmanjšanje hiperinsulinemije pri materi in večji odpornosti proti insulinu, ki se pojavi med nosečnostjo; to zmanjša dostopnost presnovnih substratov za rast plodu.
This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.
To je mogoče pripisati vplivu pioglitazona na zmanjšanje hiperinsulinemije pri samici in večji odpornosti proti insulinu med brejostjo, zaradi česar se zmanjša dostopnost presnovnih substratov za rast plodu.
This was classified as the patient’s platelet counts being above 50 million per millilitre for at least six of the last eight weeks of the 24-week treatment period, without the need for any other medicines for ITP.
Določeno je bilo kot število bolnikovih trombocitov, ki je vsaj šest do osem zadnjih tednov 24– tedenskega zdravljenja presegalo število 50 milijonov na mililiter, ne da bi pri tem potrebovali druga zdravila za zdravljenje imunske trombocitopenične purpure.
This was compared with 23% of the patients adding placebo.
Ta delež je pri bolnikih, ki so jemali placebo, znašal okrog 23 %.
This was demonstrated in a field trial over a period of 2 years.
To je potrjeno s terensko študijo v trajanju 2 let.
This was driven by mild intensity nausea.
Poročali so predvsem o blagi navzei.
This was evidenced by a hazard ratio for death of 0.82 (95% CI, 0.68 to 0.99) among patients whose best response was stable disease or progressive disease.
To je bilo dokazano z razmerjem ogroženosti za smrt 0,82 (95-% interval zaupanja: 0,68 do 0,99) pri bolnikih, pri katerih je bil najboljši odgovor stabilna bolezen ali napredovanje bolezni.
This was followed bymonotherapy TMZ (150 - 200 mg/m²) on Days 1 - 5 of every 28-day cycle for up to 6 cycles, starting 4 weeks after the end of RT.
Temu je od prvega do petega dne vsakega 28-dnevnega cikla, do šest ciklov, sledilo samostojno zdravljenje s TMZ (v odmerku od 150 do 200 mg/m²), ki se je začelo štiri tedne po koncu obsevanja.
This was mainly caused by more patients stopping Invirase treatment rather than by any differences in the effectiveness of the medicines.
Do tega je prišlo predvsem zato, ker je več bolnikov prenehalo zdravljenje z zdravilom Invirase, ne pa zaradi razlik v učinkovitosti zdravil.
This was most distinct for patients ending on Instanyl 50 micrograms.
Ta značilnost je bila najizrazitejša pri bolnikih s 50-mikrogramskim končnim odmerkom zdravila Instanyl.
This was not considered clinically relevant.
Tega niso imeli za klinično pomembno.
This was not considered clinically significant.
Tega niso imeli za klinično pomembno.
This was not seen at doses ≤ 20 mg/kg.
Pri odmerkih ≤ 20 mg/kg tega niso opazili.
This was not seen at doses ≤ 20mg/kg.
Tega pri odmerkih ≤ 20 mg/kg niso opazili.
This was not seen at doses ≤20 mg/kg.
Pri odmerkih ≤ 20 mg/kg tega niso opazili.
This was not significantly different from the 29% (90% CI 22%-35%) reduction in AUC of SVA observed when co-administration was 12 hours apart: simvastatin 40 mg in the evening and fenofibrate 145 mg in the morning.
To ni bilo pomembno drugače od 29-odstotnega zmanjšanja AUC SVK (90-odstotni IZ 22 %–35 %), ki so ga opazili, ko so zdravili dajali z razmakom 12 ur: simvastatin 40 mg zvečer in fenofibrat 145 zjutraj.
This was observed in 10.2% of patients compared to 5.0% of patients in the control arm.
Ugotovili so ga pri 10,2 % bolnikov v skupini, ki je prejemala zdravilo Bronchitol, in pri 5,0 % bolnikov v kontrolni skupini.
This was observed in a higher proportion of patients taking methadone than those not taking methadone.
To so opažali pri večjem deležu bolnikov, ki so jemali metadon, kot pri tistih, ki niso jemali metadona.
This was related primarily to early delivery or maternal neglect of offspring, common findings in nonhuman primate studies, and considered clinically irrelevant .
To je bilo povezano predvsem s prezgodnjo skotitvijo ali maternalnim zanemarjanjem mladičev, kar je v študijah na nehumanih primatih pogosto opaženo in se ne smatra za klinično pomembno.
This was supported by clinical relevance as demonstrated by the proportions of responders and remitters and the improvement in the Clinical Global Impression – Global Improvement (CGI-I) score.
To je bilo podprto s kliničnim pomenom, kar so dokazali z deležem odzivnih bolnikov in bolnikov v remisiji in izboljšanjem ocene po lestvici CGI-I (Clinical Global Impression - Global Impovement).
This was switched to a full marketing authorisation on 17 February 2015.
To je bilo 17 februarja 2015 spremenjeno v običajno dovoljenje za promet.
This was switched to a full marketing authorisation on 20 November 2013.
To je bilo 20. novembra 2013 spremenjeno v običajno dovoljenje za promet.
This was true for all HCV genotypes, particularly Genotype 1, in which the relapse rate was reduced by 30% compared with interferon alfa- 2b monotherapy.
To je veljalo za vse HCV genotipe, a še posebej za genotip 1, kjer se je delež ponovitev zmanjšal za 30 % v primerjavi z monoterapijo z interferonom alfa-2b.
This water for injections is intended for the reconstitution of Fuzeon 90 mg/ml powder for solution for injection to obtain a solution for subcutaneous use
Ta voda za injekcije je namenjena za pripravo raztopine za injiciranje zdravila Fuzeon 90 mg/ml prašek za raztopino za injiciranje za subkutano uporabo
This water is for mixing the powder in the vial
Ta voda se uporablja za mešanje s praškom v viali,
This way, you can be sure your medicine is fully effective and you reduce the risk of the HIV- virus developing resistance to the treatment.
Če boste zdravilo jemali natančno po zdravnikovih navodilih, bo dosežena polna učinkovitost zdravila, tveganje za razvoj odpornosti virusa HIV pa se bo zmanjšalo.
This will allow enough time for all the medicine to go from the pen to under your skin.
Tako bo na voljo dovolj časa, da pride celoten odmerek zdravila iz peresnika pod kožo.
This will allow quick identification of new safety information.
Tako bodo na voljo nove informacije o njegovi varnosti.
This will allow your doctor to prescribe the right dose of CELSENTRI for you.
Tako vam bo zdravnik lahko predpisal pravilni odmerek zdravila CELSENTRI.
This will be a slightly lower dose of 2 mg/kg.
Ta odmerek bo nekoliko manjši, 2 mg/kg.
This will be based on the child’s body surface area in metres squared.
Odvisen je od otrokove telesne površine v kvadratnih metrih.
This will be based on the results of your blood tests and on your general condition (see section 2 “What you need to know before you take Revlimid”).
To bo temeljilo na rezultatih vaših krvnih preiskav in na vašem splošnem stanju (glejte poglavje 2 “Kaj morate vedeti, preden boste vzeli zdravilo Revlimid”).
This will be done before you start using Betaferon, regularly after treatment with Betaferon has been initiated and periodically whilst you are on it, even if you have no particular symptoms.
Preiskave je treba opraviti preden začnete uporabljati zdravilo Betaferon, redno po začetku zdravljenja z zdravilom Betaferon in v presledkih med njegovo uporabo, tudi če nimate posebnih simptomov.
This will be followed by a “maintenance phase” - during this time you will be given Gazyvaro every 2 months for up to 2 years as long as your disease does not progress.
Temu bo sledilo vzdrževalno zdravljenje – med tem časom boste v naslednjih dveh letih dobili zdravilo Gazyvaro vsaka 2 meseca, dokler vaša bolezen ne napreduje.
This will be given as 1 g in the morning and then 1 g in the evening.
Dobili boste 1 g zjutraj in 1 g zvečer.
This will be given as a 2.5mg tablet.
Tega boste prejeli kot 2,5 mg tableto.
This will be increased every 5 – 7 days as directed by your doctor until your symptoms are controlled (maintenance dose).
Odmerek boste po zdravnikovih navodilih vsakih 5 do 7 dni povečevali, dokler ne bodo simptomi minili (vzdrževalni odmerek).
This will be provided for all the approved indications:
To se izvede pri vseh odobrenih indikacijah:
This will be repeated every 2 weeks for the first 3 months after starting the therapy.
Prve 3 mesece po uvedbi zdravljenja se bo ta preiskava ponavljala vsaka 2 tedna.
This will cause any air bubbles to rise to the top.
Tako se bodo zračni mehurčki dvignili na vrh.
This will cover information on the risk of kidney disease and the measures to reduce this risk, including appropriate screening and monitoring of patients.
To gradivo bo zajemalo informacije o tveganju za nastanek ledvične bolezni in ukrepe za zmanjšanje tega tveganja, vključno z ustreznim presejevanjem in spremljanjem bolnikov.
This will depend on your child’s weight and the results of a blood test carried out before the start of the treatment to measure the amount of IgE in his/her blood.
To je odvisno od otrokove telesne mase in rezultatov krvne preiskave, ki jo bo otrok opravil pred začetkom zdravljenja, da bi izmerili količino protiteles IgE v njegovi krvi.
This will depend on your weight and what the medicine is being used for.
Odvisen bo od vaše telesne mase in od tega, čemu je uporabljeno zdravilo.
This will depend on, for example: which other medicines you have already taken for HIV which medicines your HIV is resistant to.
To bo na primer odvisno od tega: katera druga zdravila proti virusu HIV ste že jemali, proti katerim zdravilom je HIV pri vas odporen.